Cytek Biosciences, Inc.
corporate_fare Company Profile
Cytek Biosciences, Inc. (NASDAQ:CTKB) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 14 items for CTKB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for CTKB spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Cytek 10-Q: Q3 Net Loss Widens to $6.1M; New ITC and Delaware Suits Filed Against Beckman Coulter
- Cytek Holds Guidance Midpoint as Gross Margin Jumps 590 bps, Revenue Up 2%
- Cytek Hit With $56.1M Patent Verdict in Beckman Coulter Case
- Cytek Biosciences Raises Full-Year Outlook Despite Slight Q2 Revenue Miss
- Cytek Q2 Loss Deepens as Litigation Costs Surge Ahead of Trial
Financial Snapshot
Short Interest & Short Volume
3.56 days to coverFINRA reported short interest of 4,105,921 shares in CTKB as of the October 30, 2026 settlement, a 6.9% decrease from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 20.7% of CTKB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.